May 25, 2017
Recommended Topic Related To:


"The U.S. Food and Drug Administration announced today that injectable drugs used in total parenteral nutrition (TPN) in critical shortage will be imported into the United States and available to patients this week.

TPN is an intravenous"...





Included as part of the PRECAUTIONS section.


Hypersensitivity Reactions

Life-threatening anaphylactic reactions (respiratory distress, shock, angioedema) have occurred after Lymphazurin (isosulfan blue) 1% administration. Reactions are more likely to occur in patients with a history of bronchial asthma, allergies, drug reactions or previous reactions to triphenylmethane dyes. Monitor patients closely for at least 60 minutes after administration of Lymphazurin (isosulfan blue) 1%. Trained personnel should be available to administer emergency care including resuscitation.

Precipitation of Lymphazurin (isosulfan blue) 1% by Lidocaine

The admixture of Lymphazurin (isosulfan blue) 1% (with local anesthetics (i.e. lidocaine)) in the same syringe results in an immediate precipitation of 4 - 9% drug complex. Use a separate syringe to administer a local anesthetic.

Interference with Oxygen Saturation and Methemoglobin Measurements

Lymphazurin (isosulfan blue) 1% interferes with measurements of oxygen saturation in peripheral blood by pulse oximetry and can cause falsely low readings. The interference effect is maximal at 30 minutes and minimal generally by four hours after administration. Arterial blood gas analysis may be needed to verify decreased arterial partial pressure of oxygen.

Lymphazurin (isosulfan blue) 1% may also cause falsely elevated readings of methemoglobin by arterial blood gas analyzer. Therefore, co-oximetry may be needed to verify methemoglobin level.

Nonclinical Toxicology

Carcinogenesis, Mutagenesis, Impairment of Fertility

Long-term studies in animals have not been performed to evaluate the carcinogenic potential of Lymphazurin (isosulfan blue) 1%. Reproduction studies in animals have not been conducted and, therefore, it is unknown if a problem concerning mutagenesis or impairment of fertility in either males or females exists.

Teratogenic Effects

Pregnancy Category C. Animal reproduction studies have not been conducted with Lymphazurin (isosulfan blue) 1%. It is not known whether Lymphazurin (isosulfan blue) 1% can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Lymphazurin (isosulfan blue) 1% should be given to a pregnant woman only if clearly needed.

Use In Specific Populations

Nursing Mothers

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Lymphazurin™ 1% (isosulfan blue) is administered to a nursing mother.

Pediatric Use

Safety and effectiveness of Lymphazurin™ 1% (isosulfan blue) in children have not been established.

This monograph has been modified to include the generic and brand name in many instances.

Last reviewed on RxList: 4/21/2008


Report Problems to the Food and Drug Administration


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Women's Health

Find out what women really need.

Use Pill Finder Find it Now See Interactions

Pill Identifier on RxList

  • quick, easy,
    pill identification

Find a Local Pharmacy

  • including 24 hour, pharmacies

Interaction Checker

  • Check potential drug interactions
Search the Medical Dictionary for Health Definitions & Medical Abbreviations